can skinny people take semaglutide Shot Injections: The Reality of Quick Fixes – Functional Patterns Consumers must be protected from

, GLP-1

Treating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges

Study Design: Participants who achieved average 20.9% weight loss on tirzepatide over 36 weeks were randomized to either: Continue tirzepatide Switch to placebo Results at 88 Weeks (52 weeks after randomization): Continued Tirzepatide: Additional 5.5% weight loss Total weight loss: 25.3% from baseline 89.5% maintained at least 80% of initial weight loss Switched to Placebo: 14% weight regain Total weight loss: 9.9% from baseline Only 16.6% maintained at least 80% of initial weight loss Key Takeaway: Continued treatment is essential for maintaining weight loss

95% CI [0.760.94]) and HF hospitalisation (HR 0.92